01
Launch
Learn your trial, your patients, and your enrollment landscape before a dollar moves.
Is time running out for your trial?
With our AI and Data-driven system, we accelerate your trial recruitment from rollout to closeout.
With our AI and Data-driven system, we accelerate your trial recruitment from rollout to closeout.
Most recruitment is a patchwork: an agency here, a database there, site feedback somewhere else, and nobody accountable to enrollment.
Campaigns launch. Reports circulate. The timeline keeps slipping.
Learn your trial, your patients, and your enrollment landscape before a dollar moves.
Continuous signal detection. Identify what's working before it becomes a milestone problem.
Reallocate, reposition, recalibrate. Learning to change in days — not the next quarterly review.
Each case below is drawn from a completed engagement: enrollment status at intake, operational changes made, and outcome at closeout.
A Phase 2/3 neuropsychology trial had spent 2.5 years below recruitment pace. Strict eligibility criteria, an underdiagnosed indication, and low public awareness had stalled progress. We rebuilt the funnel from the top with custom pre-screening, multichannel media, and conversion-focused digital infrastructure, then closed the trial five months ahead of deadline.
Our team was named as authors on a multicenter, double-blind, randomized controlled trial evaluating early outpatient COVID-19 treatment, sponsored by Johns Hopkins University.
Selected from peer-reviewed studies published in 2022 for scientific innovation, contribution to understanding of human disease, and potential impact on treatment.
A COVID-19 convalescent plasma trial at Johns Hopkins was severely underperforming in a hostile environment: politicized media, competing studies, and platform-level ad restrictions blocking reach. We deployed a fully integrated program across owned, earned, and paid channels alongside a multilingual HIPAA-compliant call center, driving a tenfold increase in enrolled patients within a year.
Share your trial and we'll reply with next steps.
